Mid-Atlantic BioTherapeutics
Mid-Atlantic BioTherapeutics (MABT) is a biotechnology company founded in 2011 focused on developing novel treatments for hard-to-treat diseases, especially neurological disorders such as Alzheimer's, Parkinson's, and ALS, as well as infectious diseases like rabies. The company leverages proprietary technologies and artificial intelligence to accelerate drug discovery and development, aiming to address unmet medical needs with innovative immunotherapy platforms like IMT504. MABT has achieved orphan drug designation for rabies and is advancing clinical development and commercialization of therapies targeting neurodegenerative and infectious diseases. The company collaborates with partners such as Accelero Biostructures to identify novel drug candidates and applies cutting-edge AI-driven computational methods to enhance therapeutic precision and efficacy.
Mid-Atlantic BioTherapeutics
Mid-Atlantic BioTherapeutics (MABT) is a biotechnology company founded in 2011 focused on developing novel treatments for hard-to-treat diseases, especially neurological disorders such as Alzheimer's, Parkinson's, and ALS, as well as infectious diseases like rabies. The company leverages proprietary technologies and artificial intelligence to accelerate drug discovery and development, aiming to address unmet medical needs with innovative immunotherapy platforms like IMT504. MABT has achieved orphan drug designation for rabies and is advancing clinical development and commercialization of therapies targeting neurodegenerative and infectious diseases. The company collaborates with partners such as Accelero Biostructures to identify novel drug candidates and applies cutting-edge AI-driven computational methods to enhance therapeutic precision and efficacy.